LeonaBio, Inc. Research and Development Expense
LeonaBio, Inc. (LONA) reported Research and Development Expense of $12.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- LeonaBio, Inc. research and development expense for the quarter ending 2026-06-30 was $12.70M, a 246.95% increase year-over-year.
- LeonaBio, Inc. research and development expense for the quarter ending 2026-03-31 was $11.26M, a 161.79% increase year-over-year.
- LeonaBio, Inc. research and development expense for the quarter ending 2025-12-31 was $6.71M, a 28.37% decline year-over-year.
- LeonaBio, Inc. research and development expense for the quarter ending 2025-09-30 was $2.83M, a 84.24% decline year-over-year.
- LeonaBio, Inc. research and development expense for fiscal 2025 was $17.50M, a 75.24% decline from fiscal 2024.
- LeonaBio, Inc. research and development expense for fiscal 2024 was $70.68M, a 24.64% decline from fiscal 2023.
- LeonaBio, Inc. research and development expense for fiscal 2023 was $93.79M, a 52.59% increase from fiscal 2022.
- LeonaBio, Inc. research and development expense for fiscal 2022 was $61.46M, a 43.63% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.70M 10-Q · filed 2026-08-14 | $23.96M 10-Q · filed 2026-08-14 | $30.68M derived: sum of 3 quarters · filed 2026-08-14 | $33.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $11.26M 10-Q · filed 2026-05-07 | $17.97M derived: sum of 2 quarters · filed 2026-05-07 | $20.80M derived: sum of 3 quarters · filed 2026-05-07 | $24.46M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.54M derived: sum of 2 quarters · filed 2026-03-31 | $13.20M derived: sum of 3 quarters · filed 2026-08-14 | $17.50M 10-K · filed 2026-03-31 |
| 2025-09-30 | $2.83M 10-Q · filed 2025-11-06 | $6.49M derived: sum of 2 quarters · filed 2026-08-14 | $10.79M 10-Q · filed 2025-11-06 | $20.16M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.66M 10-Q · filed 2026-08-14 | $7.96M 10-Q · filed 2026-08-14 | $17.33M derived: sum of 3 quarters · filed 2026-08-14 | $35.26M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.30M 10-Q · filed 2026-05-07 | $13.67M derived: sum of 2 quarters · filed 2026-05-07 | $31.59M derived: sum of 3 quarters · filed 2026-05-07 | $53.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $27.29M derived: sum of 2 quarters · filed 2026-03-31 | $49.45M derived: sum of 3 quarters · filed 2026-03-31 | $70.68M 10-K · filed 2026-03-31 |
| 2024-09-30 | $17.92M 10-Q · filed 2025-11-06 | $40.08M derived: sum of 2 quarters · filed 2025-11-06 | $61.31M 10-Q · filed 2025-11-06 | $84.99M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $22.15M 10-Q · filed 2025-08-07 | $43.39M 10-Q · filed 2025-08-07 | $67.07M derived: sum of 3 quarters · filed 2025-08-07 | $94.27M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $21.24M 10-Q · filed 2025-05-09 | $44.92M derived: sum of 2 quarters · filed 2025-05-09 | $72.12M derived: sum of 3 quarters · filed 2025-05-09 | $93.73M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $23.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $50.88M derived: sum of 2 quarters · filed 2025-02-27 | $72.50M derived: sum of 3 quarters · filed 2025-02-27 | $93.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $27.20M 10-Q · filed 2024-11-07 | $48.82M derived: sum of 2 quarters · filed 2024-11-07 | $70.11M 10-Q · filed 2024-11-07 | $85.35M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.61M 10-Q · filed 2024-08-01 | $42.91M 10-Q · filed 2024-08-01 | $58.14M derived: sum of 3 quarters · filed 2024-08-01 | $75.11M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $21.29M 10-Q · filed 2024-05-15 | $36.53M derived: sum of 2 quarters · filed 2024-05-15 | $53.49M derived: sum of 3 quarters · filed 2024-05-15 | $68.30M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $32.20M derived: sum of 2 quarters · filed 2024-02-22 | $47.00M derived: sum of 3 quarters · filed 2024-02-22 | $61.46M 10-K · filed 2024-02-22 |
| 2022-09-30 | $16.96M 10-Q · filed 2023-11-09 | $31.77M derived: sum of 2 quarters · filed 2023-11-09 | $46.23M 10-Q · filed 2023-11-09 | $58.85M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $14.80M 10-Q · filed 2023-08-10 | $29.26M 10-Q · filed 2023-08-10 | $41.88M derived: sum of 3 quarters · filed 2023-08-10 | $52.59M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $14.46M 10-Q · filed 2023-05-11 | $27.08M derived: sum of 2 quarters · filed 2023-05-11 | $37.78M derived: sum of 3 quarters · filed 2023-05-11 | $49.81M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $12.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $23.32M derived: sum of 2 quarters · filed 2023-03-23 | $35.35M derived: sum of 3 quarters · filed 2023-03-23 | $42.79M 10-K · filed 2023-03-23 |
| 2021-09-30 | $10.71M 10-Q · filed 2022-11-10 | $22.73M derived: sum of 2 quarters · filed 2022-11-10 | $30.18M 10-Q · filed 2022-11-10 | $35.36M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $12.02M 10-Q · filed 2022-08-15 | $19.47M 10-Q · filed 2022-08-15 | $24.66M derived: sum of 3 quarters · filed 2022-08-15 | $30.49M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $7.45M 10-Q · filed 2022-05-12 | $12.63M derived: sum of 2 quarters · filed 2022-05-12 | $18.46M derived: sum of 3 quarters · filed 2022-05-12 | $20.14M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $5.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $11.02M derived: sum of 2 quarters · filed 2022-03-28 | $12.69M derived: sum of 3 quarters · filed 2022-03-28 | $13.29M 10-K · filed 2022-03-28 |
| 2020-09-30 | $5.83M 10-Q · filed 2021-11-10 | $7.51M derived: sum of 2 quarters · filed 2021-11-10 | $8.10M 10-Q · filed 2021-11-10 | $8.76M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.68M 10-Q · filed 2021-08-16 | $2.27M 10-Q · filed 2021-08-16 | $2.93M derived: sum of 3 quarters · filed 2021-08-16 | $3.95M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $592.00K 10-Q · filed 2021-05-13 | $1.25M derived: sum of 2 quarters · filed 2021-05-13 | $2.28M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.68M derived: sum of 2 quarters · filed 2021-03-25 | $3.79M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $1.03M 10-Q · filed 2020-11-12 | $3.13M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |